AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01851486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Clonidine 0.15 mg
Study NCT01851486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: naloxone 0.15 mg/kg
Study NCT01851486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT01851486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01851486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Study NCT01851486 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT03473964 — intervention group
Intervention type: DRUG
Intervention: H.P. Acthar gel
Description: H.P. Acthar gel:~Injection 40 mg twice weekly
Study NCT01932151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Terlipressin and albumin
Description: Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water.
Study NCT03466619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inflatable penile prosthesis (IPP)
Description: inflatable penile prosthesis (IPP)
Study NCT01161095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Description: Mirena (Bayer)- Levonorgestrel-Intrauterine System
Study NCT01161095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS
Description: Mirena (Bayer)- Levonorgestrel-Intrauterine System
Study NCT01161550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Study NCT01161550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Study NCT01161550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT01397123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training teachers on healthier lifestyles
Description: During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
Study NCT01806324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL040XC
Description: single dose
Study NCT01806324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan + Atorvastatin
Description: Single dose
Study NCT03582072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: letter from the CMO
Description: informed GPs that: The great majority (80%) of practices in England reduced or stabilised their antibiotic prescribing rates in 2016/17. However, your practice is in the minority that have increased their prescribing by more than 4%.\*
Study NCT02678845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment according to the Collabri model
Description: The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
Study NCT04388267 — intervention group
Intervention type: DRUG
Intervention: Fluid challenge
Description: All patients who met the inclusion criteria will receive a standardised bolus of 250 ml of crystalloid in 5 minutes administered by hand with a 50 ml syringe.~During the study period, hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected for 20 minutes prior to the intervention (fluid challenge), during the fluid challenge and 25 minutes after completion.~The total duration of the intervention (fluid loading) is 5 min. The total duration of hemodynamic parameters recording is 60 min.
Study NCT03724539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STRIPA intervention
Description: STRIPA is a Dutch software-based tool for the support of the pharmaceutical analysis by 1) taking into account the predictable adverse medication effects, 2) advising safe and appropriate therapy using established STOPP/START criteria, 3) interaction monitoring, and 4) appropriate dosing in accordance with renal function. It represents a highly efficient and user-friendly software engine, which is capable of individually screening the clinical status and pharmacological therapy of older patients with multimorbidity, which can define optimal drug therapy, and which can highlight the adverse drug reaction risk. A summary of these outputs will be used as STRIPA recommendations, which will, if applicable, be implemented by GPs and patients.~Prior to the STRIPA medication review, the necessary patient information will be loaded from the FIRE database that contains data from more than 300 Swiss GP practices.
Study NCT01161550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA)
Study NCT01161550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Study NCT00517439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 24 weeks
Study NCT00517439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus
Description: 1000/1200mg po daily for 24 weeks
Study NCT00517439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 micrograms sc weekly for 24 weeks
Study NCT00517439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: 180 micrograms sc weekly for 24 weeks
Study NCT00517439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 90 micrograms sc weekly for 24 weeks
Study NCT00517439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4588161
Description: 1000mg po bid for 24 weeks
Study NCT00517439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4588161
Description: 500mg po bid for 24 weeks
Study NCT00517439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4588161
Description: 1500mg po bid for 24 weeks
Study NCT02640625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic compound
Description: Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
Study NCT02877654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy with biopsies in the left colon to assess intestinal permeability
Description: Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit).
Study NCT00824551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 2 sessions of HBOT ( HDMC 14)
Study NCT00824551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patient will undergo standard care
Study NCT04432493 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
Study NCT04432493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
Study NCT04432493 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation (rTMS)
Description: Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
Study NCT04432493 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation (rTMS)
Description: Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
Study NCT02438956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Setria glutathione supplement
Description: 500 mg/day capsule taken in the morning for 120 days.
Study NCT02438956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crystalline Cellulose
Description: 500 mg/day capsule taken in the morning for 120 days.
Study NCT02209402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
Study NCT01467115 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
Study NCT01467115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
Study NCT01467115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
Study NCT01467115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
Study NCT01467115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoetin
Description: Subcutaneous or intravenous
Study NCT01467115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
Study NCT01467115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
Study NCT01467115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
Study NCT03820453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tribulus Terrestris
Description: The experimental arm will receive a dietary supplement to increase the libido and sexual function
Study NCT03820453 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: The control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics
Study NCT01449110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in primary cardiovascular prevention (PP)
Description: 12 months follow-up:~1. capsule/day of placebo (350 mg maltodextrin) for 6 months~2. capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months
Study NCT01449110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in secondary prevention
Description: 12 months follow-up:~1. capsule/day (350 mg maltodextrin) for 6 months~2. capsules/day (350 mg + 350 mg maltodextrin) for 6 months
Study NCT01449110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape extract in primary prevention (PP)
Description: 12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months
Study NCT01449110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape extract in SP
Description: 12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months
Study NCT01449110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol-enriched grape extract in PP
Description: Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months
Study NCT01449110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol-enriched grape extract in SP
Description: Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months
Study NCT00537732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole
Description: 20 mg daily
Study NCT00537732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole
Description: 20 vs. 60 mg daily, genotype dependent
Study NCT02720601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan & Capecitabine
Description: Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
Study NCT02115841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enraf-Nonius Muscle stimulator
Description: The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
Study NCT03051984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (\~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
Study NCT02073032 — intervention group
Intervention type: OTHER
Intervention: No intervention, only observation
Study NCT02485652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: 800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria.
Study NCT04963114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: art therapy
Description: guided art tour and workshop
Study NCT03724539 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Patients being assigned to the control arm will be treated in accordance with standard care. They will receive a sham intervention, which consists of a usual medication review by their GP and a shared decision making between patient and GP.
Study NCT03914781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIN-SELF Program
Description: The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
Study NCT04461171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery
Description: Undergo an enhanced recovery after surgery program
Study NCT02905331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.
Study NCT02905331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.